A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs EYS 606 (Primary)
- Indications Uveitis
- Focus Adverse reactions; First in man
- Sponsors Eyevensys
- 13 Sep 2017 EYS606 has been granted an Orphan drug designation by the European Medicines Agency (EMA) for the treatment of NIU, according to an Eyevensys media release.
- 09 May 2017 Professor Antoine Brezin is the principal investigator of the trial, according to an Eyevensys media release,
- 09 May 2017 According to an Eyevensys media release, the first patient has been successfully treated in this trial and initial trial results are expected in the first half of 2018.